Merck & Co. (NYSE:MRK) CEO Kenneth Frazier unloaded 10,047 shares of Merck & Co. stock on the open market in a transaction dated Thursday, April 10th. The shares were sold at an average price of $57.24, for a total value of $575,090.28. Following the completion of the transaction, the chief executive officer now directly owns 310,494 shares of the company’s stock, valued at approximately $17,772,677. Merck & Co., Inc. (NYSE:MRK) shares after opening at $55.55 moved to $56.60 on last trade day and at the end of the day closed at $55.92. Company price to sales ratio in past twelve months was calculated as 3.73 and price to cash ratio as 9.40. Merck & Co., Inc. (NYSE:MRK) showed a negative weekly performance of -0.36%.
Medtronic (NYSE:MDT) VP Richard Kuntz sold 2,512 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $60.98, for a total value of $153,181.76. Following the completion of the sale, the vice president now directly owns 104,736 shares of the company’s stock, valued at approximately $6,386,801. Medtronic, Inc. (NYSE:MDT) shares fell -1.50% in last trading session and ended the day on $59.20. MDT return on equity ratio is recorded as 19.10% and its return on assets is 10.00%. Medtronic, Inc. (NYSE:MDT) yearly performance is 27.97%.
Illumina (NASDAQ:ILMN) CEO Jay T. Flatley unloaded 30,000 shares of the stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $139.90, for a total value of $4,197,000.00. Following the transaction, the chief executive officer now directly owns 381,262 shares of the company’s stock, valued at approximately $53,338,554. Illumina, Inc. (NASDAQ:ILMN) shares moved down -0.37% in last trading session and was closed at $135.24, while trading in range of $129.11 – $141.00. Illumina, Inc. (NASDAQ:ILMN) year to date (YTD) performance is 22.29%.
Vertex Pharmaceuticals (NASDAQ:VRTX) Director Elaine Ullian sold 2,500 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $70.00, for a total transaction of $175,000.00. Following the completion of the transaction, the director now directly owns 5,265 shares in the company, valued at approximately $368,550. Vertex Pharmaceuticals Inc.orporated (NASDAQ:VRTX) weekly performance is -4.22%. On last trading day company shares ended up $63.06. Vertex Pharmaceuticals Inc.orporated (NASDAQ:VRTX) distance from 50-day simple moving average (SMA50) is -18.77%. Analysts mean target price for the company is $91.66.